BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene, Ltd. and Ensem Therapeutics, Inc. announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.